← All trials
NCT05135312
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 9, 2021
- Primary completion
- Aug 8, 2022
- Completion date
- Aug 8, 2022
- First posted
- Nov 26, 2021
- Last posted
- Nov 26, 2021
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- OptiSkin MedicalLead sponsor
- AmgenCollaborator
- OptiSkin MedicalReponsible party - principal investigator
- OptiSkin MedicalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.